Business Wire

NetWitness Announces New Threat Detection and Intelligence Capabilities with NetWitness Platform XDR 12

15.9.2022 02:59:00 EEST | Business Wire | Press release

Share

NetWitness, a globally trusted provider of cybersecurity technologies and incident response, today announced the upcoming availability of NetWitness Platform XDR 12 later this month, the industry’s most comprehensive extended detection and response solution. NetWitness Platform XDR 12 is the first solution on the market to deliver on the promise of extended detection and response.

Developed in response to real-world customer needs, NetWitness Platform XDR 12 is focused on sophisticated detection, which is at the core of effective threat defense. The updated platform offers full visibility into all key data planes across an organization including network, logs, endpoint, and Internet of Things (IoT); full Security Orchestration, Automation, and Response (SOAR); a complete Threat Intelligence Platform (TIP); User and Entity Behavior Analytics (UEBA); and new asset analytics and prioritization, all easily viewed in a single interface and a unified data model.

“Effective security teams need tools that can bring insights together from multiple data sources and deliver comprehensive, actionable alerting,” said Kevin Bowers, Director, Product Management at NetWitness. “Embracing this principle, NetWitness built XDR functionality long before the phrase was popularized. This release delivers the promise of XDR: the ability for security teams to detect attacks across all an organization's information assets and infrastructure, and to stop them before they cause damage.”

The updated NetWitness Platform XDR solution features new and enhanced analytics capabilities that can find known and unknown threats even faster, to reduce dwell time and allow response and remediation before adversaries can successfully execute a harmful attack. NetWitness Platform XDR 12 also makes it easier for users to deploy and manage threat detection content bundles that target specific threat categories, vertical industries, and use cases, providing more effective threat coverage.

NetWitness began as a government-sponsored research project to inspect network packets for cyberthreats and to develop the tools to detect and respond to them. Since then, the technology has continuously evolved in real-world usage to tackle today’s most complex attacks. NetWitness now features fully integrated components for network, log, endpoint and IoT detection and response. With its long history and global footprint, NetWitness Platform XDR integrates directly with the world’s most critical and widely deployed tools, as well as many specialized and industry-specific solutions.

“XDR concepts aren’t new, but they’re incredibly important,” said Bill Hart, Senior Product Manager for NetWitness Platform XDR. “We long ago integrated the primary data planes – network, endpoint, log and IoT – into a unified data model allowing for advanced detection capabilities that are independent of the data source. Others that have recently adopted an XDR strategy still analyze different data types in silos and attempt to correlate at the alert level; this leaves visibility gaps. Sophisticated, multi-vector attack detection requires holistic, data level integration and analysis.”

To learn more about the new NetWitness Platform XDR 12, visit netwitness.com. Additionally, those attending the Black Hat Conference in Las Vegas on August 6-11 are encouraged to stop by the NetWitness booth (2941) for a NetWitness Platform XDR 12 product demo.

About NetWitness

NetWitness, an RSA® Group Business, provides comprehensive and highly scalable threat detection and response capabilities for organizations around the world. The NetWitness Platform delivers complete visibility combined with applied threat intelligence and user behavior analytics to detect, prioritize, investigate threats, and automate response. This empowers security analysts to be more efficient and stay ahead of business-impacting threats. For more information, visit netwitness.com.

©2022 RSA Security LLC or its affiliates. All rights reserved. RSA and the RSA logo are trademarks of RSA Security LLC or its affiliates. For a list of RSA trademarks visit https://www.rsa.com/en-us/company/rsa-trademarks . Other trademarks are trademarks of their respective owners. RSA believes the information in this document is accurate. The information is subject to change without notice.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
SHIFT Communications
netwitness@shiftcomm.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release

Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 08:09:00 EEST | Press release

LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 08:00:00 EEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye